Cost and Health Care Utilization Implications of Bariatric Surgery Versus Intensive Lifestyle and Medical Intervention for Type 2 Diabetes.
Cost and Health Care Utilization Implications of Bariatric Surgery Versus Intensive Lifestyle and Medical Intervention for Type 2 Diabetes.
复制标题
DOI：
10.1002/oby.21927
复制
发表时间：
2017-09
期刊：
影响因子：
--
通讯作者：
Arterburn DE
中科院分区：
文献类型：
--
作者：
Banerjee S;Garrison LP Jr;Flum DR;Arterburn DE
比较随机分为Roux-en-Y胃旁路手术（RYGB）和强化生活方式和医疗干预（ILMI）两组的肥胖和2型糖尿病（T2DM）患者的成本和医疗保健利用情况。该分析（N=745）基于一项小型随机对照试验（RCT）的两年随访；2011 - 2012年间从团体健康合作社招募肥胖和2型糖尿病的成年患者。将随机分为RYGB组（N=15）和ILMI组（N=17）的患者进行比较。在随访期间，RYGB患者与ILMI患者没有明显的成本节约。RYGB患者与ILMI患者在第2年的药房费用比第0年低约900美元；然而，与第0年相比，手术患者在随访期间的住院和急诊室费用更高。与随机患者相比，非随机患者在第0年和第2年的中位总成本更高。减肥手术在短期内不会节省成本。此外，参加RYGB随机对照试验的患者的成本可能与未参加随机对照试验的患者不同，这表明在使用此类数据推断一般肥胖人群时应谨慎。
To compare the cost and healthcare utilization of patients with obesity and Type 2 diabetes mellitus (T2DM) randomized into either Roux-en-Y gastric bypass (RYGB) surgery or an intensive lifestyle and medical intervention (ILMI). This analysis (N=745) is based on two-year follow-up of a small randomized controlled trial (RCT); adult patients with obesity and T2DM were recruited between 2011 and 2012 from Group Health Cooperative. Comparisons were made for patients randomized into either RYGB (N=15) or ILMI (N=17). There were no significant cost savings for RYGB vs. ILMI patients through the follow-up years. Pharmacy cost was lower for RYGB vs. ILMI patients by about $900 in year 2 vs. year 0; however, inpatient and emergency room costs were higher for surgery patients in follow-up years relative to year 0. Median total cost for non-randomized patients was higher in year 0 and in year 2 compared to randomized patients. Bariatric surgery is not cost-saving in the short term. Moreoover, the costs of patients who enter into RCTs of RYGB may differ from that of those who do not enter RCTs, suggesting use of caution when using such data to draw inferences about the general population with obesity.
登录
查看更多内容
影响因子：
3.1
作者：
Arterburn, David;Flum, David R.;Cummings, David E.
通讯作者：
Cummings, David E.
影响因子：
8.2
作者：
Cummings DE;Arterburn DE;Westbrook EO;Kuzma JN;Stewart SD;Chan CP;Bock SN;Landers JT;Kratz M;Foster-Schubert KE;Flum DR
通讯作者：
Flum DR
DOI：
10.1001/jama.2014.732
发表时间：
2014-02-26
期刊：
JAMA
影响因子：
--
作者：
Ogden CL;Carroll MD;Kit BK;Flegal KM
通讯作者：
Flegal KM
影响因子：
3.1
作者：
Finkelstein, Eric A.;Allaire, Benjamin T.;Hale, Brent C.
通讯作者：
Hale, Brent C.
影响因子：
--
作者：
Maciejewski, Matthew L.;Livingston, Edward H.;Arterburn, David E.
通讯作者：
Arterburn, David E.